ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.Nature communications · 2026Trial
- Cell culture in salivary gland tumor research: molecular insights of pathogenic targets and personalized medicine.Cytotechnology · 2025Review
- Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review).Oncology letters · 2025Review
- Characterization of uniquely tumorigenic cancer stem cells in salivary gland adenoid cystic carcinoma.Frontiers in oral health · 2025Article
- Establishment and characterization of cMYB-expressing human salivary adenoid cystic carcinoma cell lines (UM-HACC-14, UM-HACC-6) and matching patient-derived xenograft model (UM-PDX-HACC-14).Oral surgery, oral medicine, oral pathology and oral radiology · 2024Article
- MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.Pharmacological reviews · 2024Review
- Molecular Aspects of Mucoepidermoid Carcinoma and Adenoid Cystic Carcinoma of the Salivary Gland.Head and neck pathology · 2024Review
- Therapeutic inhibition of Bmi-1 ablates chemoresistant cancer stem cells in adenoid cystic carcinoma.Oral oncology · 2023Article
- Establishment and validation of nomograms to predict survival probability of advanced malignant pleural mesothelioma based on the SEER database and a Chinese medical institution.Frontiers in endocrinology · 2023Article
- Bmi-1: A master regulator of head and neck cancer stemness.Frontiers in oral health · 2023Review
- p53 Inhibits Bmi-1-driven Self-Renewal and Defines Salivary Gland Cancer Stemness.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Metastatic Adenoid Cystic Carcinoma: Genomic Landscape and Emerging Treatments.Current treatment options in oncology · 2022Review
- Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma.Current oncology reports · 2022Review
- MI-773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1.Oncology letters · 2021Article
- mTOR Inhibition Ablates Cisplatin-Resistant Salivary Gland Cancer Stem Cells.Journal of dental research · 2021Article
- Survival of salivary gland cancer stem cells requires mTOR signaling.Cell death & disease · 2021Article
- Systemic therapies for salivary gland adenoid cystic carcinoma.American journal of cancer research · 2021Review
- Establishment of patient-derived xenograft models of adenoid cystic carcinoma to assess pre-clinical efficacy of combination therapy of a PI3K inhibitor and retinoic acid.American journal of cancer research · 2021Article
- LINC00657/miR-26a-5p/CKS2 ceRNA network promotes the growth of esophageal cancer cells via the MDM2/p53/Bcl2/Bax pathway.Bioscience reports · 2020Article
- The role of E3 ubiquitin ligase HECTD3 in cancer and beyond.Cellular and molecular life sciences : CMLS · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Felipe NörDepartment of Cariology, Restorative Sciences, and Endodontics, University of Michigan School of Dentistry, Ann Arbor, Michigan.
Kristy A WarnerDepartment of Cariology, Restorative Sciences, and Endodontics, University of Michigan School of Dentistry, Ann Arbor, Michigan.
Zhaocheng ZhangDepartment of Cariology, Restorative Sciences, and Endodontics, University of Michigan School of Dentistry, Ann Arbor, Michigan.
Gerson A AcasiguaDepartment of Cariology, Restorative Sciences, and Endodontics, University of Michigan School of Dentistry, Ann Arbor, Michigan.
Alexander T PearsonDepartment of Cariology, Restorative Sciences, and Endodontics, University of Michigan School of Dentistry, Ann Arbor, Michigan.
Samuel A KerkDepartment of Cariology, Restorative Sciences, and Endodontics, University of Michigan School of Dentistry, Ann Arbor, Michigan.
Joseph I HelmanDepartment of Oral and Maxillofacial Surgery, University of Michigan School of Dentistry, Ann Arbor, Michigan.
Manoel Sant'Ana FilhoDepartment of Oral Pathology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Shaomeng WangDepartment of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan.
Jacques E NörDepartment of Cariology, Restorative Sciences, and Endodontics, University of Michigan School of Dentistry, Ann Arbor, Michigan. jenor@umich.edu.
University of Michigan · USUniversidade Federal do Rio Grande do Sul · BR
Funding
Therapeutic Potential and Mechanism of Action of Potent Small Molecule InhibitorsP50CA097248 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WOLF, GREGORY T · 2002 to 2013
$25.3MSalivary gland cancer stem cellsR01DE021139 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jacques Eduardo Nor · 2011 to 2026
$5.8MTherapeutic Inhibition of MDM2/Bcl-2 in Pre-clinical Models of Adenoid Cystic CarR01DE023220 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NOR, JACQUES EDUARDO · 2012 to 2015
$1.5MA reasoned approach to combination therapy development in head and neck cancerK08DE026500 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PEARSON, ALEXANDER THOMAS · 2016 to 2020
$800kEndothelial and head & neck cancer stem cell crosstalks and resistance to therapyR21DE019279 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NOR, JACQUES EDUARDO · 2008 to 2009
$419kNCI NIH HHS P50 CA097248NIDCR NIH HHS K08 DE026500NIDCR NIH HHS R01 DE021139NIDCR NIH HHS R01 DE023220NIDCR NIH HHS R21 DE019279
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsApoptosisCarcinoma, Adenoid CysticCell Line, TumorCell ProliferationCisplatinFemaleHumansMaleMiceNeoplasm ProteinsNeoplasm Recurrence, LocalProtein Interaction MapsProto-Oncogene Proteins c-mdm2Spiro CompoundsTumor Suppressor Protein p53CisplatinMDM2 protein, humanNeoplasm ProteinsProto-Oncogene Proteins c-mdm2Spiro CompoundsTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.